EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A quantitative Lewy-fold-specific alpha-synuclein seed amplification assay as a progression marker for Parkinson’s disease

Alexander M Bernhardt, Sebastian Longen, Svenja V Trossbach, Marcello Rossi, Daniel Weckbecker, Felix Schmidt, Alexander Jäck, Sabrina Katzdobler, Urban M Fietzek, Endy Weidinger, Carla Palleis, Viktoria Ruf und 6 weitere

Acta Neuropathologica · 20.02.2025 · 149 (1)

DOI: 10.1007/s00401-025-02853-y ↗

Kurz gefasst

Fachartikel in der Zeitschrift Acta Neuropathologica, online erschienen am 20.02.2025. Verfasst von Alexander M Bernhardt und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Ludwig-Maximilians-Universität München, Munich, Germany. Hauptthemen laut MEDLINE: alpha-Synuclein, Parkinson Disease, Lewy Body Disease. Die Arbeit wurde bisher 46-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bundesministerium für Bildung und Forschung.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Misfolded α-synuclein (αSyn) is the hallmark of α-synucleinopathies such as Parkinson’s disease (PD), dementia with Lewy bodies (DLB), and multiple system atrophy (MSA). While seed amplification assays (SAA) have demonstrated ultrasensitive detection of misfolded αSyn, they have been primarily used reliably to provide binary (positive/negative) results for diagnostic purposes. We developed an SAA with enhanced specificity for Lewy-fold α-synucleinopathies and introduced a quantifiable measure correlating with clinical severity. Cerebrospinal fluid (CSF) of 170 patients with neurodegenerative diseases and controls was analyzed. Blinded measurements demonstrated 97.8% sensitivity and 100% specificity for Lewy-fold α-synucleinopathies, correctly identifying PD and DLB while excluding MSA. In addition, we validated the strain specificity of the assay by testing brain homogenates from 30 neuropathologically confirmed cases. A novel Lewy-fold pathology (LFP) score based on positive signals in a dilution series provided a quantitative measure of αSyn seeds. The LFP score significantly correlated with motor and cognitive impairment presented by Hoehn and Yahr stage, MDS-UPDRS III, and MoCA. Longitudinal tracking in seven PD cases showed progressive LFP score increases corresponding with clinical deterioration, highlighting the assay’s potential for monitoring disease progression at an individual level. Our Lewy-fold-specific SAA enhances ante-mortem diagnosis and differentiates Lewy-fold α-synucleinopathies from MSA. Unlike previous assays, the LFP score offers a quantitative assessment, showing promise as a progression marker and pharmacodynamic biomarker for αSyn-targeting therapies. This represents an important step toward developing an αSyn SAA that could help to track disease progression quantitatively, with potential applications in both clinical diagnostics and therapeutic trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

alpha-SynucleinParkinson DiseaseLewy Body DiseaseHumansDisease ProgressionMaleFemaleAgedBiomarkersMiddle AgedAged, 80 and over

Substanzen

alpha-SynucleinBiomarkers

Autor:innen und Institutionen

  • Department of Neurology, Ludwig-Maximilians-Universität München, Munich, Germany.
  • Aesku.Diagnostics GmbH, Wendelsheim, Germany.
  • MODAG GmbH, Wendelsheim, Germany.
  • Department of Biomedical and Neuromotor Sciences (DiBiNeM), University of Bologna, Bologna, Italy.
  • Munich Cluster for Systems Neurology (SyNergy), Munich, Germany.
  • Center for Neuropathology and Prion Research, Faculty of Medicine, Ludwig-Maximilians-University Munich, Munich, Germany.

Förderung

  • Bundesministerium für Bildung und Forschung

Zitieren

APA

Bernhardt, A. M., Longen, S., Trossbach, S. V., Rossi, M., Weckbecker, D., Schmidt, F., Jäck, A., Katzdobler, S., Fietzek, U. M., Weidinger, E., Palleis, C., Ruf, V., Baiardi, S., Parchi, P., Höglinger, G. U., Matthias, T., Levin, J., & Giese, A. (2025). A quantitative Lewy-fold-specific alpha-synuclein seed amplification assay as a progression marker for Parkinson’s disease. Acta Neuropathologica, 149(1). https://doi.org/10.1007/s00401-025-02853-y

Vancouver

Bernhardt AM, Longen S, Trossbach SV, Rossi M, Weckbecker D, Schmidt F, et al. A quantitative Lewy-fold-specific alpha-synuclein seed amplification assay as a progression marker for Parkinson’s disease. Acta Neuropathologica. 2025;149(1). doi:10.1007/s00401-025-02853-y

BibTeX
@article{Bernhardt2025,
  author = {Bernhardt, Alexander M and Longen, Sebastian and Trossbach, Svenja V and Rossi, Marcello and Weckbecker, Daniel and Schmidt, Felix and Jäck, Alexander and Katzdobler, Sabrina and Fietzek, Urban M and Weidinger, Endy and Palleis, Carla and Ruf, Viktoria and Baiardi, Simone and Parchi, Piero and Höglinger, Günter U and Matthias, Torsten and Levin, Johannes and Giese, Armin},
  title = {A quantitative Lewy-fold-specific alpha-synuclein seed amplification assay as a progression marker for Parkinson’s disease},
  journal = {Acta Neuropathologica},
  year = {2025},
  volume = {149},
  number = {1},
  doi = {10.1007/s00401-025-02853-y}
}
Kostenlos starten →